SYL-1801 is under clinical development by Sylentis SAU and currently in Phase I for Choroidal Neovascularization. According to GlobalData, Phase I drugs for Choroidal Neovascularization have a 95% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how SYL-1801’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
SYL-1801 is under development for the treatment of wet form of neovascular age related macular degeneration, diabetic retinopathy and choroidal neovascularization. It is administered by ophthalmic routes. The drug candidate is a siRNA developed based on SIRFINDER technology.
Sylentis SAU overview
Sylentis SAU (Sylentis), a subsidiary of Pharma Mar SA, is a biotechnology company that researches and develops new medicaments based on RNA interference gene silencing technology. The company develops products, which include bamosiran and SYL1001. It offers products for various therapeutic areas such as glaucoma, ocular allergies, dry eye syndrome and neurodegenerative diseases. Sylentis also conducts research on ophthalmology, inflammation, central nervous system, formulations and medications. The company collaborates with various pharmaceutical companies and institutions to markets its products. Sylentis is headquartered in Madrid, Spain.
For a complete picture of SYL-1801’s drug-specific PTSR and LoA scores, buy the report here.